OUR TECHNOLOGY
FORESEE is developing an ultra-thin, battery-free intravascular microsensing platform designed to acquire complementary physiological measurements and support more comprehensive cardiovascular monitoring.
Volume-conduction powering concept from FORESEE's existing technical material.
AN INTEGRATED SYSTEM
01
Designed to acquire physiological information from within the cardiovascular system.
02
Provides wireless power and supports data acquisition and communication with the implant.
03
Intended to present physiological information and support physician-directed monitoring.
The platform also includes a delivery system designed to deploy the intravascular microsensor in a branch of the pulmonary artery. It is the means of implantation, rather than part of the daily home measurement routine.
COMPLEMENTARY PHYSIOLOGICAL INFORMATION
FORESEE's platform is designed to integrate complementary measurements within a single intravascular device. Each parameter contributes a different type of physiological information.
Hemodynamic information.
Measurements sensitive to changes in thoracic fluid status.
Information about the heart's mechanical activity.
Complementary physiological information.
WIRELESS POWER AND COMMUNICATION
An external unit applies high-frequency current bursts through external electrodes. These currents flow through tissue by volume conduction and are picked up by electrodes at the ends of the elongated implant.
The implant rectifies the received currents to power its electronics. The architecture also supports bidirectional communication with the external unit [5].
The volume-conduction approach is designed to operate without an implanted electrochemical battery or a conventional receiving coil. Powering and communication functions can be integrated with sensing electronics in an application-specific integrated circuit (ASIC).
ULTRA-THIN INTRAVASCULAR DESIGN
Reducing reliance on bulky powering components supports the development of thin, elongated devices. Miniaturized integrated electronics are a foundation for FORESEE's intravascular microsensing platform.
Earlier eAXON research: an intramuscular microstimulator, not the FORESEE cardiovascular device [5].
The earlier eAXON devices used a hermetic capsule housing an integrated circuit within a flexible, elongated body. This research provides context for the powering and integration approach; it does not establish the dimensions, materials or validation status of the FORESEE cardiovascular implant.
DESIGNED FOR EVERYDAY USE
The target routine is an approximately five-minute measurement at home. This intended workflow and physician-directed patient self-management model are under development, not an already validated clinical service.
01
The patient uses the external unit as part of the intended home measurement routine.
02
The external unit delivers wireless power to the implant through volume conduction.
03
The powered implant acquires physiological measurements and communicates with the external unit.
04
Information becomes available through the digital monitoring system to support a physician-defined care plan.
BEYOND SINGLE-PARAMETER SYSTEMS
Single-parameter implantable monitoring focuses on one physiological signal. FORESEE's active sensing architecture is designed to bring multiple complementary measurements together within a single battery-free intravascular device.
Designed to integrate complementary physiological measurements within one active electronic platform.
Volume-conduction powering and communication without an implanted battery or conventional receiving coil.
An architecture intended to reduce the internal footprint of powering and electronic components.
Intended to support structured home measurements and physician-directed monitoring; workload and clinical benefits remain to be evaluated.
FROM RESEARCH TO CLINICAL TRANSLATION
FORESEE is progressing through prototype development and preclinical validation. Its cardiovascular platform is under development and is not presented as an approved or commercially available device.
FORESEE is a spin-off of Universitat Pompeu Fabra (UPF). Its work builds on research in bioelectrical phenomena and wireless powering of implantable devices.
2
Protecting FORESEE's core technology
[5] J Neural Eng. 2022 Sep 14;19(5). Read publication.
[6] IEEE Trans Biomed Eng. 2023 Feb;70(2):659–670. Read publication.
[7] J Neuroeng Rehabil. 2024 Jan 3;21(1):4. Read publication.
These publications concern foundational research and earlier implantable technologies; they should not be interpreted as clinical validation of the FORESEE cardiovascular platform.
Patent family 1: EP3788948A1
Patent family 2: EP4052643B1
We welcome conversations with clinical, technological, and investment partners interested in advancing cardiovascular monitoring.
Contact Us